Form 8-A12B Lakewood-Amedex Biothera

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR 12(g) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

Nevada		20-5274304
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

8031 Cooper Creek Blvd., Unit 103 University Park, Florida		34201
(Address of principal executive offices)		(Zip Code)

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class to be registered		Name of each exchange on which each class is to be registered
Common Stock, par value $0.0001 per share		The Nasdaq Stock Market LLC

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

 

Securities Act Registration Statement or Regulation A offering statement file number to which this form relates:

 

333-292664

 

Securities to be registered pursuant to Section 12(g) of the Act: None.

 

 

 

Item 1. Description of Registrant’s Securities to be Registered.

 

The securities to be registered hereby are the shares of the common stock, par value $0.0001 per share (the “Common Stock”) of Lakewood-Amedex Biotherapeutics Inc. (the “Company”). The description of the Common Stock contained in the section entitled “Description of Capital Stock” in the prospectus included in the Company’s Registration Statement on Form S-1 (File No. 333-292664), initially filed with the U.S. Securities and Exchange Commission on January 9, 2026, as amended from time to time (the “Registration Statement”), to which this Form 8-A relates, is incorporated herein by reference. Any form of prospectus or prospectus supplement to the Registration Statement that includes such descriptions and that is subsequently filed is also incorporated by reference herein.

 

Item 2. Exhibits.

 

Pursuant to the instructions for Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Company are registered on The Nasdaq Stock Market LLC, and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Company has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

Lakewood-Amedex Biotherapeutics Inc.
By:	/s/ Kelvin Cooper
Name:	Kelvin Cooper
Title:	Chief Executive Officer

 

Dated: April 17, 2026

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Guardian Metal Resources PLC Announces Tungsten Mining & Processing Strategic Partnership
• Mirantis First to Future-Proof AI Infrastructure with Integrated Day-Zero Support for Current and Next-Generation NVIDIA Architectures
• Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors